FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168985770> ?p ?o ?g. }

• W3168985770 endingPage "2962" @default.
• W3168985770 startingPage "2949" @default.
• W3168985770 abstract "Advances in immunostimulatory and anti-immunosuppressive therapeutics have revolutionized cancer treatment. However, novel immunotherapeutics with these dual functions are not frequently reported. Here we describe the creation of a heterodimeric bifunctional fusion molecule, HCW9218, constructed using our soluble tissue factor (TF)-based scaffold technology. This complex comprises extracellular domains of the human transforming growth factor-β (TGF-β) receptor II and a human interleukin-15 (IL-15)/IL-15 receptor α complex. HCW9218 can be readily expressed in CHO cells and purified using antibody-based affinity chromatography in a large-scale manufacturing setting. HCW9218 potently activates mouse natural killer (NK) cells and CD8+ T cells in vitro and in vivo to enhance cell proliferation, metabolism, and antitumor cytotoxic activities. Similarly, human immune cells become activated with increased cytotoxicity following incubation with HCW9218. This fusion complex also exhibits TGF-β neutralizing activity in vitro and sequesters plasma TGF-β in vivo. In a syngeneic B16F10 melanoma model, HCW9218 displayed strong antitumor activity mediated by NK cells and CD8+ T cells and increased their infiltration into tumors. Repeat-dose subcutaneous administration of HCW9218 was well tolerated by mice, with a half-life sufficient to provide long-lasting biological activity. Thus, HCW9218 may serve as a novel therapeutic to simultaneously provide immunostimulation and lessen immunosuppression associated with tumors. Advances in immunostimulatory and anti-immunosuppressive therapeutics have revolutionized cancer treatment. However, novel immunotherapeutics with these dual functions are not frequently reported. Here we describe the creation of a heterodimeric bifunctional fusion molecule, HCW9218, constructed using our soluble tissue factor (TF)-based scaffold technology. This complex comprises extracellular domains of the human transforming growth factor-β (TGF-β) receptor II and a human interleukin-15 (IL-15)/IL-15 receptor α complex. HCW9218 can be readily expressed in CHO cells and purified using antibody-based affinity chromatography in a large-scale manufacturing setting. HCW9218 potently activates mouse natural killer (NK) cells and CD8+ T cells in vitro and in vivo to enhance cell proliferation, metabolism, and antitumor cytotoxic activities. Similarly, human immune cells become activated with increased cytotoxicity following incubation with HCW9218. This fusion complex also exhibits TGF-β neutralizing activity in vitro and sequesters plasma TGF-β in vivo. In a syngeneic B16F10 melanoma model, HCW9218 displayed strong antitumor activity mediated by NK cells and CD8+ T cells and increased their infiltration into tumors. Repeat-dose subcutaneous administration of HCW9218 was well tolerated by mice, with a half-life sufficient to provide long-lasting biological activity. Thus, HCW9218 may serve as a novel therapeutic to simultaneously provide immunostimulation and lessen immunosuppression associated with tumors." @default.
• W3168985770 created "2021-06-22" @default.
• W3168985770 creator A5005650643 @default.
• W3168985770 creator A5008440450 @default.
• W3168985770 creator A5011687963 @default.
• W3168985770 creator A5022576143 @default.
• W3168985770 creator A5022589010 @default.
• W3168985770 creator A5026169690 @default.
• W3168985770 creator A5032881324 @default.
• W3168985770 creator A5032944185 @default.
• W3168985770 creator A5036726873 @default.
• W3168985770 creator A5038003715 @default.
• W3168985770 creator A5053215237 @default.
• W3168985770 creator A5054294469 @default.
• W3168985770 creator A5059906816 @default.
• W3168985770 creator A5063244333 @default.
• W3168985770 creator A5066424143 @default.
• W3168985770 creator A5069160791 @default.
• W3168985770 creator A5071853809 @default.
• W3168985770 creator A5077990075 @default.
• W3168985770 creator A5080930080 @default.
• W3168985770 creator A5089232714 @default.
• W3168985770 creator A5089746537 @default.
• W3168985770 date "2021-10-01" @default.
• W3168985770 modified "2023-10-17" @default.
• W3168985770 title "Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors" @default.
• W3168985770 cites W1572418079 @default.
• W3168985770 cites W1949767377 @default.
• W3168985770 cites W1964081206 @default.
• W3168985770 cites W1970563382 @default.
• W3168985770 cites W1977258469 @default.
• W3168985770 cites W2002595222 @default.
• W3168985770 cites W2007197271 @default.
• W3168985770 cites W2031976232 @default.
• W3168985770 cites W2051816002 @default.
• W3168985770 cites W2057623222 @default.
• W3168985770 cites W2062929087 @default.
• W3168985770 cites W2070346776 @default.
• W3168985770 cites W2095138364 @default.
• W3168985770 cites W2115953354 @default.
• W3168985770 cites W2136280424 @default.
• W3168985770 cites W2140081727 @default.
• W3168985770 cites W2175045656 @default.
• W3168985770 cites W2214536705 @default.
• W3168985770 cites W2261928305 @default.
• W3168985770 cites W2320026459 @default.
• W3168985770 cites W2347012456 @default.
• W3168985770 cites W2417856398 @default.
• W3168985770 cites W2518755163 @default.
• W3168985770 cites W2521333197 @default.
• W3168985770 cites W2528662867 @default.
• W3168985770 cites W2781947653 @default.
• W3168985770 cites W2782838719 @default.
• W3168985770 cites W2783370150 @default.
• W3168985770 cites W2788914092 @default.
• W3168985770 cites W2791205277 @default.
• W3168985770 cites W2794125175 @default.
• W3168985770 cites W2795455773 @default.
• W3168985770 cites W2796164027 @default.
• W3168985770 cites W2798233554 @default.
• W3168985770 cites W2806809152 @default.
• W3168985770 cites W2884035880 @default.
• W3168985770 cites W2898701288 @default.
• W3168985770 cites W2906781095 @default.
• W3168985770 cites W2911188335 @default.
• W3168985770 cites W2917714624 @default.
• W3168985770 cites W2936243442 @default.
• W3168985770 cites W3006876324 @default.
• W3168985770 cites W3007540950 @default.
• W3168985770 cites W3028523516 @default.
• W3168985770 cites W3032431385 @default.
• W3168985770 cites W3045946240 @default.
• W3168985770 cites W3096075115 @default.
• W3168985770 cites W3179318855 @default.
• W3168985770 cites W4211181525 @default.
• W3168985770 doi "https://doi.org/10.1016/j.ymthe.2021.06.001" @default.
• W3168985770 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8531151" @default.
• W3168985770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34091051" @default.
• W3168985770 hasPublicationYear "2021" @default.
• W3168985770 type Work @default.
• W3168985770 sameAs 3168985770 @default.
• W3168985770 citedByCount "15" @default.
• W3168985770 countsByYear W31689857702022 @default.
• W3168985770 countsByYear W31689857702023 @default.
• W3168985770 crossrefType "journal-article" @default.
• W3168985770 hasAuthorship W3168985770A5005650643 @default.
• W3168985770 hasAuthorship W3168985770A5008440450 @default.
• W3168985770 hasAuthorship W3168985770A5011687963 @default.
• W3168985770 hasAuthorship W3168985770A5022576143 @default.
• W3168985770 hasAuthorship W3168985770A5022589010 @default.
• W3168985770 hasAuthorship W3168985770A5026169690 @default.
• W3168985770 hasAuthorship W3168985770A5032881324 @default.
• W3168985770 hasAuthorship W3168985770A5032944185 @default.
• W3168985770 hasAuthorship W3168985770A5036726873 @default.
• W3168985770 hasAuthorship W3168985770A5038003715 @default.
• W3168985770 hasAuthorship W3168985770A5053215237 @default.
• W3168985770 hasAuthorship W3168985770A5054294469 @default.
• W3168985770 hasAuthorship W3168985770A5059906816 @default.

• next